Taken together, these findings suggest that miR-485-3p/PGC-1α pathway is a promising therapeutic target in ALS and support the potential of BMD-001S as a novel treatment strategy for the disease. The gene discussed is PPARGC1A; the disease is amyotrophic lateral sclerosis.